证券代码：300147 证券简称：香雪制药 编号：20150513 | --- | --- | --- | |----------------|------------------------------|----------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 深圳市创海富信资产管理有限公司：许均华 | | 人员姓名 | | 南山资本东海长基投资基金：李思婷 | | | | 创金合信基金管理有限公司：皮劲松 | | | | 上海兴聚投资管理有限公司：朱节 | | | | 诺安基金管理有限公司：罗春蕾，杜佐远 | | | | 深圳前海汇杰达理资本有限公司：解睿 | | | 易方达基金管理有限公司：郭杰 | | | | 天弘基金管理有限公司：郭相博 | | | | 华创证券有限责任公司：王昊 | ...

Group 1: Company Development Plans - The company is focusing on the development of traditional Chinese medicine formula granules and is conducting research on processes and quality standards [3] - The company is optimistic about the market prospects for traditional Chinese medicine slices and aims to promote their industrialization [3] Group 2: Clinical Research and Collaborations - The first phase of clinical research on specific T cell adoptive immunotherapy for solid tumors in collaboration with Hospital 458 has been completed, and data is currently being organized [3] - The company is cautiously considering mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Strategic Partnerships - The company has signed letters of intent for cooperation with Hubei Tianji Traditional Chinese Medicine Slices Co., Ltd. and Anhui Dechang Pharmaceutical Slices Co., Ltd., and is progressing according to plan [4] Group 4: Sales and Growth - Jiujibiotech has made adjustments to its sales policies and is expected to achieve steady growth this year compared to last year [4] Group 5: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [4]

证券代码：300147 证券简称：香雪制药 编号：20141106 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中国中投证券有限责任公司：池陈森； | | 人员姓名 | | 广州广证恒生证券投资咨询有限公司：张伟； | | | 广东银石投资有限公司：谢成长； | | | | 招商证券股份有限公司：王准飞 | | | | 国信证券股份有限公司：邵燕芳； | | | | 大成基金管理有限公司：杨挺。 | | | 时间 | 2014-11-6 15:00 | 至 17:00 | | 地点 | 公 ...

Group 1: Company Development Strategy - The company focuses on the development of traditional Chinese medicine modernization as its strategic direction, emphasizing endogenous growth, external expansion, business model innovation, and leading-edge technology as four driving forces [3][4] - The company has competitive advantages in the development strategy, operational mechanism, management model, technology, and marketing aspects of the traditional Chinese medicine sector [3] Group 2: Clinical Research and Collaborations - The first phase of the clinical research project on specific T cell adoptive immunotherapy for solid tumors in collaboration with 458 hospitals has been completed, with the initial clinical summary report drafted [4] - The company is cautiously pursuing mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Employee Stock Ownership and Banking Progress - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [5] - The establishment of Huacheng Bank is currently in the application process [5]

证券代码：300147 证券简称：香雪制药 编号：20160608 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 汇添富基金管理股份有限公司：张韡 | | | 富国基金管理有限公司：娄圣睿 | | | | 华夏基金管理有限公司：陈斌 | | | | | 易方达基金管理有限公司：王俊杰 | | | | 农银汇理基金管理有限公司：徐治彪 | | | 广发证券股份有限公司:吴文华 | | | | | 广州瑞民投资管理有限公司：黄晓坤 | | 时间 | 2016-06-08 | | | 地点 | 公司会议室 | | | ...

Group 1: Marketing and Sales Strategy - The company is transitioning its traditional Chinese medicine sales model from a distributor-based approach to a self-managed direct sales model, enhancing control over terminal sales [2][3] - The sales team is being restructured to operate OTC and prescription drugs independently, while also implementing nationwide price maintenance and abandoning low-bid regions [3] Group 2: Development Plans - The company aims to establish technical standards for approximately 400 varieties of traditional Chinese medicine granules within two years, focusing on industry policy and quality standards [3] - Production bases are being developed in Ningxia Longde and Sichuan Nanchong to support the future production of granules [3] Group 3: Clinical Projects - The company is collaborating with 458 hospitals on a specific T-cell therapy project for solid tumors, with the first phase of clinical trials completed and the second phase currently in patient selection [4] Group 4: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan is currently at a loss, and the company will consider follow-up measures before the plan's expiration, subject to official announcements [4] Group 5: Future Directions - The company continues to focus on the pharmaceutical and healthcare industry, with an emphasis on traditional Chinese medicine and plans to expand into precision medicine [4] - The investment in Huacheng Life Insurance is based on future business synergies, with the company awaiting regulatory approval [5]

广州市香雪制药股份有限公司 2022 年第三季度报告 证券代码：300147 证券简称：香雪制药 公告编号：2022—082 广州市香雪制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营业收入（元） | 554,612,486.43 | -20.88% | 1,745,600,746.67 | -21.95 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,190,988,260.24, a decrease of 22.44% compared to ¥1,535,511,803.60 in the same period last year[22]. - The net profit attributable to shareholders was a loss of ¥170,458,116.42, representing a decline of 438.83% from a profit of ¥50,307,171.06 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was a loss of ¥222,166,077.35, down 1,088.59% from ¥22,472,960.09 in the same period last year[22]. - The cash flow from operating activities was ¥57,684,468.54, a decrease of 52.34% compared to ¥121,038,887.20 in the previous year[22]. - The basic earnings per share were -¥0.26, a decline of 425.00% from ¥0.08 in the same period last year[22]. - The operating profit was -115.11 million yuan, a decrease of 230.08% year-on-year[41]. - The company reported a net profit of -222,166,077.35 yuan for the current period, a decrease of 1,088.59% compared to the same period last year, which had a profit of 22,472,960.09 yuan[186]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,941,414,003.48, down 3.86% from ¥11,380,592,438.86 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 5.76% to ¥2,775,750,574.46 from ¥2,945,552,554.18 at the end of the previous year[22]. - The company's total liabilities decreased from CNY 4,840,261,233.04 in the first half of 2021 to CNY 4,561,330,326.26 in the first half of 2022, reflecting a reduction of approximately 5.8%[198]. - The total current liabilities amounted to CNY 4,487,635,433.95 in the first half of 2022, down from CNY 4,781,507,886.47 in the first half of 2021, a decrease of approximately 6.1%[198]. - The company's long-term borrowings decreased from CNY 22,850,577.72 in the first half of 2021 to CNY 16,224,329.01 in the first half of 2022, a reduction of about 29%[198]. Investment and R&D - The company is developing a new drug for glioblastoma treatment (KX02), which is a key part of its new drug development and technological innovation[41]. - The company has completed Phase I clinical trials for a new TCR cell therapy drug (TAEST16001) and is preparing to start Phase II clinical research[41]. - The company’s subsidiary, Xiangxue Life Sciences, is advancing two clinical products: TAEST16001 for soft tissue sarcoma and TAEST1901 for primary liver cancer, with the former entering Phase II clinical trials[32]. - The company has completed the registration of 35 national standard varieties for formula granules and has made progress in the development of various antiviral products[32][34]. - Research and development expenses increased by 81.28% to approximately ¥40.92 million, up from ¥22.57 million in the previous year[54]. Operational Changes and Strategies - The company is focusing on optimizing its asset structure and resource allocation to enhance overall operational efficiency[79]. - The company is strategically expanding its market presence by deepening marketing reforms and increasing control over terminal channels[80]. - The company is exploring various R&D models, including independent development and technology transfer, to strengthen its technical reserves[39]. - The company has outlined potential risks and countermeasures in its management discussion and analysis section[3]. - The company is actively optimizing its management structure and has begun divesting non-core subsidiaries to improve asset liquidity and operational efficiency[86]. Legal and Compliance Issues - The company is currently facing multiple legal lawsuits, with significant amounts involved: 300 million CNY from a lawsuit by Kangxiang Co., 299 million CNY from Huasheng Fund Management, 123 million CNY from Guangzhou High-tech Zone Financing Leasing Co., and 280 million CNY from Guangzhou High-tech Zone Investment Group[94]. - The company is actively seeking reasonable solutions to the lawsuits and is in communication with relevant parties to protect shareholder interests[94]. - The company received a warning letter from the China Securities Regulatory Commission regarding compliance issues[150]. - The company was fined 250,000 yuan for violating advertising laws, but the impact on operations was not significant[121]. Shareholder and Capital Management - The company plans not to distribute cash dividends or issue bonus shares[4]. - The company has implemented a stock incentive plan, granting 8,767,604 restricted shares at a price of 3.32 CNY per share to 203 individuals, including directors and key personnel[100]. - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 24.75% of the shares, totaling 163,670,578 shares, with a decrease of 3,130,000 shares during the reporting period[166]. - The total amount of shares pledged by the largest shareholder is 158,215,629 shares, which represents a significant portion of their holdings[169]. - The company has a total of 3,414,001 shares available for release from restrictions, accounting for 0.52% of the total share capital[103]. Environmental and Social Responsibility - The company has established a third-party monitoring scheme for environmental emissions, with monthly reports submitted to the environmental protection bureau[109]. - The company has actively promoted energy-saving measures and adhered to national environmental protection standards[111]. - The company has made charitable donations valued at 1.9273 million RMB to various social organizations, including medical and educational foundations[111]. - The company has implemented a quality management system to ensure product quality and has maintained zero production or equipment accidents in the first half of 2022[111].

Financial Performance - The net profit attributable to shareholders for 2021 was -688.4691 million RMB, primarily impacted by the pandemic, medical policies, market competition, impairment provisions, and financial costs[5]. - The company's operating revenue for 2021 was CNY 2,970,575,841.91, a decrease of 3.30% compared to CNY 3,072,090,655.97 in 2020[23]. - The net profit attributable to shareholders was a loss of CNY 688,469,145.4, representing a decline of 799.51% from a profit of CNY 98,420,950.34 in 2020[22]. - The total profit for 2021 was CNY -635.78 million, a decline of 482.68% compared to the previous year[61]. - The company's gross profit margin declined by approximately 6.08% due to increased promotional efforts, including price reductions and higher discount rates[76]. - The company reported a net loss of CNY 658,697,282.65, primarily due to provisions for goodwill impairment and asset impairment[100]. - The company’s financial expenses increased by 53.72% year-on-year, impacting overall profitability[62]. Strategic Focus and Development - The company is committed to transitioning from rapid growth to high-quality development in the pharmaceutical sector[5]. - The company aims to enhance its market share by leveraging brand advantages and promoting product marketing efforts[51]. - The company is focused on maintaining a fair and efficient value distribution system to enhance team cohesion and promote sustainable business growth[190]. - The company aims to modernize traditional Chinese medicine, focusing on internal growth, external expansion, business model innovation, and cutting-edge technology[125]. - The company plans to optimize its asset structure and resource allocation to enhance core competitiveness and overall market position[51]. - The company is exploring potential mergers and acquisitions to further strengthen its market position and expand its product portfolio[166]. Industry Challenges and Opportunities - The pharmaceutical industry is facing challenges and opportunities due to the dual impact of the COVID-19 pandemic and medical policies, leading to difficulties in raw material procurement, production organization, and logistics[5]. - The medical reform policies, including "volume-based procurement" and dynamic adjustments to the medical insurance catalog, have had a short-term negative impact on the traditional Chinese medicine industry[5]. - The company has faced significant pressure on internal cost control due to policies like "volume-based procurement" and dynamic adjustment of the medical insurance catalog, leading to intense competition in the industry[48]. - The ongoing medical reform policies are pressuring the pharmaceutical industry, necessitating the company to seek new growth opportunities amidst competitive challenges[137]. Research and Development - The company is currently conducting Phase I clinical trials for its T-cell immunotherapy product TAEST16001, aimed at treating synovial sarcoma[60]. - The company has developed a complete TCR-T technology platform for tumor-specific antigen discovery and TCR screening, achieving international advanced levels[64]. - The company’s R&D efforts focus on innovative products, including antiviral oral liquids and environmentally friendly medical aerosol products[63]. - Research and development expenses increased by 35.25% to CNY 90.60 million, reflecting higher investment in new drug development projects[95]. Governance and Compliance - The company emphasizes strict compliance with information disclosure regulations, ensuring accurate and timely communication with investors[155]. - The company has a robust governance structure that aligns with legal and regulatory requirements, with no significant discrepancies noted[156]. - The company has established a complete system for labor, personnel, and salary management, independent from its controlling shareholders[159]. - The company actively engages with stakeholders to balance interests and promote sustainable development[156]. Market Trends and Sales Performance - In the first half of 2021, the pharmaceutical industry saw a sales growth of 8.8%, with total sales reaching 839.3 billion yuan[35]. - The online medical and e-commerce market saw a significant sales increase of 60.9% compared to 2020, driven by the pandemic[35]. - The traditional Chinese medicine segment's revenue was CNY 120,895.98 million, an increase of 10.01% year-on-year[73]. - The pharmaceutical distribution segment achieved revenue of CNY 86,886.01 million, up 40.54% year-on-year[73]. Employee and Management Structure - The total number of employees at the end of the reporting period was 3,378, with 1,082 in the parent company and 1,905 in major subsidiaries[189]. - The company has implemented a salary policy that includes basic salary, performance salary, bonuses, social security, housing fund, and living allowances to motivate employees[190]. - The company has a total of 706 technical personnel, 680 sales personnel, and 1,192 production personnel, indicating a diverse workforce[189]. - The company has a comprehensive compensation structure based on performance and responsibilities for its executives[175]. Financial Management and Investments - The company plans to optimize its debt structure through self-funding and utilizing remaining credit lines to manage repayment obligations[138]. - The company reported a total of CNY 747,351,437.08 in ongoing non-equity investments, with a cumulative actual investment of CNY 4,461,468.00 by the end of the reporting period[114]. - The company made a significant equity investment of CNY 1,500,000,000 in Guangzhou Xianglan Health Industry Co., acquiring 100% ownership[110]. - The company sold 100% equity of Guangdong Zhaoyang Biotechnology Co., Ltd., optimizing asset structure and improving liquidity, resulting in a positive cash flow and cooperation benefits[120].

Financial Performance - The company's revenue for Q1 2022 was ¥613,719,586.39, representing a decrease of 22.41% compared to the same period last year[3] - The net profit attributable to shareholders was a loss of ¥54,380,193.73, a decline of 320.85% year-over-year[3] - The net cash flow from operating activities was negative at ¥14,969,306.51, down 131.19% from the previous year[3] - The company reported a basic earnings per share of -¥0.082, a decrease of 305.00% compared to the previous year[3] - Total operating revenue for the current period is $613.72 million, a decrease of 22.4% compared to $790.93 million in the previous period[23] - Operating profit turned negative at -$41.30 million, compared to a profit of $37.23 million in the previous period[24] - Net profit for the current period is -$41.90 million, a significant decline from a profit of $32.23 million in the previous period[24] - Basic and diluted earnings per share are both -$0.082, down from $0.040 in the previous period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,170,462,439.30, a decrease of 1.85% from the end of the previous year[4] - As of March 31, 2022, the company's total assets amounted to 11.17 billion CNY, a decrease from 11.38 billion CNY at the beginning of the year[20] - The company's total liabilities decreased to approximately 7.45 billion CNY from 7.62 billion CNY, a reduction of about 2.2%[21] - The company's cash and cash equivalents increased to approximately 356.83 million CNY from 196.12 million CNY at the beginning of the year, representing an increase of about 81.9%[19] - Accounts receivable rose to approximately 1.16 billion CNY from 1.10 billion CNY, reflecting an increase of about 6%[19] - The company reported a decrease in inventory from approximately 761.46 million CNY to 709.49 million CNY, a decline of about 6.8%[19] Investment and Financing Activities - The company received government subsidies amounting to ¥5,900,042.62 during the reporting period[6] - The investment income increased by 2454.75% due to the sale of a subsidiary, Guangzhou Xiangxue Asia Beverage Co., Ltd.[8] - Cash flow from investing activities generated a net inflow of $282.87 million, a turnaround from a net outflow of -$142.31 million in the previous period[29] - Cash flow from financing activities resulted in a net outflow of -$111.11 million, slightly improved from -$123.26 million in the previous period[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,935[10] - The company approved the repurchase and cancellation of 82,390 restricted shares at a price of 3.274 CNY per share, reducing total share capital from 661,361,435 shares to 661,279,045 shares[15] - The total number of restricted shares at the beginning of the period was 4,763,909, with no shares released or added during the reporting period[13] Corporate Actions and Developments - The company completed a capital increase of RMB 100 million for its wholly-owned subsidiary, raising its registered capital from RMB 160 million to RMB 260 million[14] - The company transferred 63% equity of its subsidiary, Guangzhou Xiangxue Asia Beverage Co., Ltd., for a total of RMB 81.9 million, with all transfer procedures completed by the end of the reporting period[14] - The company agreed to transfer a fund share of 50 million CNY from Guangzhou Huacheng Venture Capital Partnership to Jiadu Group for 56.44 million CNY, and an 18% stake in Guangzhou Huacheng Venture Capital Management for 9.52 million CNY[15] - The company decided to terminate the preparation for establishing Huacheng Life Insurance Co., Ltd., with a planned investment of 160 million CNY for a 16% stake due to macroeconomic and financial policy changes[16] - The subsidiary, Xiangxue Life Science Technology, received approval for clinical trials of the new drug TAEST1901, aimed at treating advanced liver cancer and other late-stage tumors[16] Audit and Reporting - The first quarter report has not been audited[30] - The report was presented by the Chairman, Wang Yonghui, on April 28, 2022[31]